Sat.Nov 11, 2023

article thumbnail

Detailed trial data confirm Wegovy heart benefit

Bio Pharma Dive

As GLP-1 drugs for weight loss take off, the results for Novo Nordisk’s treatment could help convince insurers to expand coverage.

Trials 299
article thumbnail

Drug Patent Expirations for the Week of November 12, 2023

Drug Patent Watch

AMRIX (cyclobenzaprine hydrochloride) Teva pharms intl Patent: 7,829,121 Expiration: Nov 14, 2023 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact… The post Drug Patent Expirations for the Week of November 12, 2023 appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 64
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Lilly Stock Slips as Patients Regain Weight After Stopping Zepbound

BioSpace

The Indiana-based pharma shed shares after a study published Monday in JAMA showed "substantial" weight gain after patients discontinued treatment with the GLP-1 receptor agonist.

52
article thumbnail

Which pharmaceutical drugs have the most drug patents in Slovakia?

Drug Patent Watch

This chart shows the drugs with the most patents in Slovakia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.… The post Which pharmaceutical drugs have the most drug patents in Slovakia? appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 59
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Amid Revenue Downturn and Staff Cuts, Catalent Looks to GLP-1

BioSpace

The company’s fiscal report for 2023 details revenue losses of $539 million and layoffs of 1,100 employees but notes that future GLP-1 manufacturing revenues could help stabilize its finances.

article thumbnail

New tentative approval for Rising drug acetylcysteine

Drug Patent Watch

Acetylcysteine is the generic ingredient in seven branded drugs marketed by Cumberland Pharms, Aspen, Eugia Pharma, Exela Pharma, Fresenius Kabi Usa, Indoco, Rising, Sagent Pharms Inc, Steriscience, Zydus Pharms, Alvogen,… The post New tentative approval for Rising drug acetylcysteine appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 59

More Trending

article thumbnail

EzriCare Eye Drops Recall: Unveiling a Nationwide Health Crisis

Roots Analysis

The Centers for Disease Control and Prevention (CDC) recently issued a formal health advisory in response to an unprecedented outbreak of carbapenem-resistant Pseudomonas aeruginosa (CRPA), a bacterium notorious for its resistance to specific antibiotics, thereby instigating severe infections in affected individuals. This concerning development has been traced back to the utilization of EzriCare Artificial Tears Eye Drops.

article thumbnail

Pfizer’s $5.4B GBT Bet Pays Off with Promising Phase II Data for Oxbryta Successor

BioSpace

Patients treated with the investigational sickle cell therapy saw an increase in hemoglobin levels and improved red blood cell parameters.

52
article thumbnail

Why Sites Prefer Onsite Monitoring vs Remote Monitoring Visits

ECRG Media's Clinical Research Podcast

Why Sites Prefer Onsite Monitoring vs Remote Monitoring Visits Don't forget to Subscribe for new content! Merch: [link] Subscribe: / eliteclinicalresearch Email: eliteclinicalgroup@gmail.com Podcast: [link] Steemit: [link] Advertise: eliteclinicalgroup@gmail.com Watch: » Industry News: [link] » All Videos: [link] » Interview Recaps: [link] » Glassdoor Reviews: [link] We do: » Insider Interviews » Resume Reviews » Question and Answer » Discuss all things Clinical Research » News and Prod

article thumbnail

Roche Partner Poseida Touts High Response Rates for Allogeneic CAR-T Therapy

BioSpace

The investigational allogeneic CAR-T therapy P-BCMA-ALLO1 appears to be more effective following strong immunosuppressive preconditioning.

52
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Autism and Maternal Immune Activation: Groundbreaking Insights

Roots Analysis

Infantile amnesia, the mysterious phenomenon where memories from early childhood seem to slip away, has long intrigued scientists and psychologists alike. Recent groundbreaking research from Trinity College Dublin has unveiled a compelling link between maternal immune activation during pregnancy, autism, and the persistence of early memories into adulthood.

article thumbnail

Opinion: Move Over mRNA; tRNAs Have Even Broader Reach

BioSpace

Transfer RNA’s unique biology could enable a mutation-specific, gene-agnostic—and more cost effective—approach to developing treatments for thousands of rare and ultra-rare diseases.

Gene 52
article thumbnail

ASH 23: CAR-T for Autoimmune, Arcellx's Multiple Myeloma Challenger and Seagen's Combo Play

BioSpace

A CAR-T cell therapy for autoimmune diseases generated significant attention at the 2023 American Society of Hematology (ASH) annual meeting and Arcellx and Seagen posted promising data.

40
article thumbnail

How Kyowa Kirin is Giving Employees a Voice in the Company's Future

BioSpace

Five years ago, Kyowa Kirin set out to expand its North America operations, adding new employees and capabilities at a rapid pace.

40
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

Bluebird’s Newly Approved SCD Gene Therapy Faces Rough Road with Hefty Price.

BioSpace

These factors, along with bluebird bio’s failure to receive a priority review voucher, all hurt the company’s stock price following Lyfgenia’s approval.